[Federal Register Volume 59, Number 100 (Wednesday, May 25, 1994)] [Unknown Section] [Page 0] From the Federal Register Online via the Government Printing Office [www.gpo.gov] [FR Doc No: 94-12734] [[Page Unknown]] [Federal Register: May 25, 1994] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 94N-0160] Solvay Animal Health, Inc., et al.; Withdrawal of Approval of NADA's AGENCY: Food and Drug Administration, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of two new animal drug applications (NADA's). One NADA is held by Solvay Animal Health, Inc., and provides for the use of a sulfaquinoxaline soluble powder. The other NADA is held by Pharmachem Corp. and provides for the use of a dextran injection. The sponsors requested withdrawal of approval of the NADA's because they no longer manufacture or distribute the products. EFFECTIVE DATE: June 6, 1994. FOR FURTHER INFORMATION CONTACT: Dianne T. McRae, Center for Veterinary Medicine (HFV-102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-1623. SUPPLEMENTARY INFORMATION: Solvay Animal Health, Inc., 1201 Northland Dr., Mendota Heights, MN 55120-1149, is the sponsor of NADA 7-285, which provides for the use of SulquinSoluble Powder (sulfaquinoxaline sodium) in making medicated poultry and cattle drinking water. Pharmachem Corp., P.O. Box 1035, Bethlehem, PA 18018, is the sponsor of NADA 12-494, which provides for use of Pharmatran (dextran injection 6 percent) as a plasma volume expander in small and large animals. By letter dated August 10, 1992, Solvay Animal Health, Inc., requested that FDA withdraw approval of NADA 7-285 and stated that it no longer manufactures or distributes the product. Similarly, in a letter dated September 10, 1992, Pharmachem Corp. requested that FDA withdraw approval of NADA 12-494 and stated that it has not marketed its product since September 1971. Therefore, under authority delegated to the Commissioner of Food and Drugs ( 21 CFR 5.10) and redelegated to the Center for Veterinary Medicine (21 CFR 5.84), and in accordance with Sec. 514.115 Withdrawal of approval of applications (21 CFR 514.115), notice is given that approval of NADA's 7-285 and 12-494 and all supplements and amendments thereto is hereby withdrawn, effective June 6, 1994. Dated: May 18, 1994. Richard H. Teske, Acting Director, Center for Veterinary Medicine [FR Doc. 94-12734 Filed 5-24-94; 8:45 am] BILLING CODE 4160-01-F